Humanis Takes a Strong Step into Psychiatric Treatment
Humanis, which continues its operations with a human-centered health philosophy, has made a significant entry into the field of psychiatric treatment. Under an agreement with AstraZeneca, the company has taken over the license and brand rights of a product used in the treatment of central nervous system diseases, whose efficacy has been scientifically proven. The product will continue to be made available to patients under the Humanis umbrella.
Operating with a human-centred health philosophy, Humanis has made an important entry into psychiatric treatment. Under an agreement with AstraZeneca, the company has acquired the marketing authorization and trademark rights for a product used in the treatment of central nervous system disorders whose efficacy is scientifically proven. The product will continue to be made available to patients under the Humanis brand.
New Step in Psychiatry
Through Liva İlaç Pazarlama Sanayi ve Ticaret A.Ş., Humanis has taken its first step into a treatment area with high demand, such as psychiatric disorders. With the transfer of marketing authorization and trademark rights, the company has not only expanded its portfolio but also added a treatment option with high accessibility and strong efficacy to its product range.
The product has been manufactured at Humanis's facilities in Çerkezköy to international quality standards since 2017. Humanis will manage the distribution, promotion and all commercial processes of the product, contributing to Turkish medicine in psychiatry through uninterrupted supply and high quality assurance.
Dr. Yalçın Yaşin: Patient-Focused Approach is Our Priority
Dr. Yalçın Yaşin, General Manager of Commercial Operations at Humanis, made the following assessment:
"The assumption by our company of the representation and supply process of the drug in Turkey is a critical step in terms of both continuity of access to treatment and continuity of safe use. With our expanding treatment areas, we aim to develop sustainable solutions that will contribute to human health in the long term."
About Humanis
Founded in 2010 within Saya Group as Pharmactive, Humanis has been operating under the same name since 2023. With its human-centred approach, the company has adopted the principle of 'sustainable health for all'; through its manufacturing facility and R&D centre in Çerkezköy, it makes significant contributions to the sector and to Turkey.
Humanis has an effective portfolio covering different areas including paediatrics, cardiology, pulmonary medicine, otolaryngology, internal medicine, infectious diseases, gastroenterology, dermatology, physical therapy and rehabilitation, orthopaedics, emergency medicine, rare diseases, psychiatry and neurology. The company continues to provide products in consumer health while pursuing its human-centred innovative health philosophy.
Gallery
